How should we treat type 2 diabetes in youth?

Pediatric Endocrinology Reviews

Volumn 3, Issue 1, 2005, Pages 33-39

  Urakami, Tatsuhiko ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Combination therapy; Diet and exercise; Insulin; Intervention; Oral hypoglycemic agents; Treatment; Type 2 diabetes in youth

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; VOGLIBOSE;

DIABETIC DIET; DIABETIC KETOACIDOSIS; DIABETIC MICROANGIOPATHY; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; JUVENILE DIABETES MELLITUS; LACTIC ACIDOSIS; LIFESTYLE; LOW CALORY DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PEDIATRICS; RISK FACTORS; WEIGHT LOSS;

EID: 32244433452     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. International Diabetes Federation. Consensus on the Aetiology of Type 2 Diabetes Mellitus. June 2002, Colombo, Sri Lanka
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431
3. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999;22:345-354
4. American Diabetes Association. Type 2 diabetes in children and adolescents (Consensus Statement): Diabetes Care 2000;25:381-389
5. Bloomgarden ZT. Type 2 diabetes in the young. The evolving epidemic. Diabetes Care 2004;27:998-1010
6. Pinhas-Hamiel O, Dolan MN, Daniels SR, Standiford D, Khoury PR, Zettler P. Increased incidence of non-insulin dependent diabetes mellitus among adolescents. J Pediatr 1996;128:608-615
7. Kitagawa T, Owada M, Urakami T, Tajima N. Epidemiology of type 1 (insulin-dependent) and type 2 (non-insulin dependent) diabetes mellitus in Japanese children: Diabetes Res Clin Pract 1994;24 (Suppl.) S7-S13
8. Kitagawa T, Owada M, Urakami T, Yamanouchi K: Increased incidence of non-insulin-dependent diabetes mellitus among Japanese school children correlates with an increased intake of animal protein and fat. Clin Pediatr 1998;37:111-115
9. Kawamura T, Kadotani S, Kimura K, Nishihara S, Inada H, Ishiki G. The epidemiological study on the prevalence rate of childhood type 2 diabetes in Osaka city of Japan using caputur mark recapture method (Abstract). Diabetes 1999;48 (Suppl. 1):A168
10. L-M Chuang, Wei J-N, Sung F-C, Lee C-Y, Lin R-S, Lin C-C, Chiang C-C; Incidence and prevalence of childhood diabetes in Taiwan: an experience with nation-wide mass screening (abstract). Diabetes Res Clin Pract 2002;56(Suppl.1):S16
11. Likitmaskul S, Kittisathavee P, Chaichanwatanakul K, Punnakanta L, Angsusingha K, Tuchinda C: Increasing prevalence of type 2 diabetes mellitus in Thai children and adolescents associated with increasing prevalence of obesity. J Pediatr Endocrinol Metab 2003;16:71-77
12. Eriksson J, Lindstrom J, Tuomilehto J. Potential for the prevention of type 2 diabetes. Br Med Bull 2001;60:183-199
13. Ludwig DS, Ebbeling C. Type 2 diabetes mellitus in children: primary care and public health considerations. JAMA 2001;286:1427-1430
14. Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, Yamada H, Muto K, Uchigata Y, Ohashi Y, Iwamoto Y. Higher incidence of diabetic nephropathy in type 2 than type 1 diabetes in early-onset diabetes in Japan. Kidney Int 2000;58:302-311
15. Krakoff J. Applying prevention studies in adults and children. Symposium on Prevention of Type 2 Diabetes in Children: Pathogenesis to Public Policy. Center for Weight and Health. September 2000, University of California, Berkley, CA
16. Dabelea D, Hanson RL, Bennet PH, Roumain J, Knowler WC, Pettitt DJ. Increasing prevalence of type II diabetes in American Indian children. Diabetologia 1998;41:904-910
17. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes. N Engl J 1986;Med 315:215-219
18. Ohki Y, Orimo Y. Screening for diabetes in obese school students. Shouni-naika 2002;34:1620-1623
19. Urakami T, Kubota S, Nitadori Y, Harada K, Oowada M, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in school children detected by urine glucose screening in Tokyo metropolitan area. Diabetes Care, in press
20. Rosenberg M, Lawrence A. Review of Primary Prevention of Type 2 Diabetes in Western Australia. October 2000, The Public Health Unit, Department of Public Health, University of Western Australia, Australia
21. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT Diabetes Study. Diabetes Care 1997;20:537-544
22. Hu FB, Manson JE, Stampeer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-797
23. Tuomilehto J, Lindstorm J, Eriksson JG, Valle TT, Hamalainen H, Hanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350
24. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle invention or metformin. N Engl J Med 2002;346:393-403
25. Trevino PR, Pugh JA, Hernandez AE, Menchaca VD, Ramirez RR, Mendoza M. Bienestar: a diabetes risk-factor prevention program. J Sch Health 1998;68:62-67.
26. Trevino PR, Dempsey L, Garcia O, Ramirez G, Yin Z. Reversing hyperglycemia in low-income Latino children participating in the Bienestar. Diabetes 2002;51 (Suppl.) 1776-P
27. Teufe NI, Ritenbaugh CK. Development of a primary prevention program: insight gained in the Zuni Diabetes Prevention Program. Clin Pediatr 1998;37:131-141
28. Donnelly JE, Jacobsen DJ, Whatley JE, Hill JO, Swift LL, Cherrington A, Polk B, Tran ZV, Reed G. Nutrition and physical activity program to attenuate obesity and promote physical and metabolic fitness in elementary school children. Obes Res 1996;4:229-243
29. Ritchie LD, Ganapathy S, Woodward-Lopez G, Gerstein DE, Fleming SE. Prevention of type 2 diabetes in youth: Etuiology, promising interventions and recommendations. Pediatr Diabet 2003;4:174-209
30. American Diabetic Association. Standards of medical Care for patients with diabetes mellitus. Diabetes Care 2002;25 (Suppl. 1):S33-S49
31. Inzucchi SE. Oral antihyperglyemic therapy for type 2 diabetes-Scientific review. JAMA 16;2002:360-372
32. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
33. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin treatment prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabet Res Clin Prac 1995;28:103-117
34. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
35. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-1349
36. Genuth S. Insulin use in NIDDM. Diabetes Care 13:1240-1246, 1990.
37. Rosetti L, Giaccari A, DeFronzo R. Glucose toxicity. Diabetes Care 1990;13:610-630
38. Owada M, Nitadori Y, Kitagawa T. Treatment of NIDDM in youth. Clinical Pediatrics 1998;37:117-122
39. Henry R, Gumbinar B. Benefits and limitations of very low-calorie diet therapy in obese NIDDM. Diabetes Care 1992;14:802-823
40. Henry R. Glucose control and insulin resistance in non-insulin diabetes mellitus. Ann Intern Med 1996;124:97-103
41. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The Essen-IIStudy. Am J Med 1997;103:483-490
42. Hasche H, Mertes G, Bruns C, Englert R, Genthner P, Heim D, Heyen P, Mahla G, Schmidt C, Schlze-Schleppinshoff B, Steger-Johannsen G. Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999;12:277-285
43. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide-plus- acarbose in non-insulin dependent diabetes mellitus. Am J Med 1995;98:443-451
44. Chiasson JL, Josse RG, Hunt JA, Plmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus: a multicenter controlled trial. Ann Intern Med 1994;121:928-935
45. Josse R. Acarbose for the treatment of type II diabetes: the result of a Canadian multi-center trial. Diabetes Res Clin Pract 1995;28 (Suppl.):167-172
46. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-754
47. Fineberg S, Schneider S. Glipizide versus tolbutamide, an open trial: Effect on insulin secretory patterns and glucose concentrations. Diabetologia 1980;18:45-54
48. Melander A, Lebovitz H, Faber C. Sulfonylureas: Why, which and how? Diabetes Care 1990;13:18-25
49. Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimeperide, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996;19:1194-1199
50. Shade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimeperide in patients with type 2 diabetes mellitus for whom die therapy is unsuccessful. J Clin Pharmacol 1998;38:636-641
51. Kolata GB. The phenformin ban: is the drug an imminent hazard? Science 1979;203:1094-1096
52. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes. N Engl J Med 1995;333:541-549
53. Crofford OB. Metformin. N Engl J Med 1995;333:588-589
54. Cuse K, DeFronzo RA. Metformin: a review of its metabolic effects: Diabetes Reviews 1998;6:89-131
55. Dorman T, Heller S, Peck G, Tattersall R. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991;14:342-344
56. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
57. Jones KL, Park JS, Arslanian S, Peterocova VA, Park JS, Tomlinson MJ. Effects of metformin in pediatric patients with type 2 diabetes, a randomized controlled trial. Diabetes Care 2002;25:89-94
58. Urakami T. A Review: Treatment for childhood type 2 diabetes. Clin Pediatr Endocrinol 2005;14:1-9
59. Silverstein JH, Rosenbloom AI. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2000;13 (Suppl. 6):13:1403-1409
60. Genuth S. Insulin use in NIDDM. Diabetes Care 1990;13:1240-1246
61. Henry R. Glucose control and insulin resistance in non-insulin diabetes mellitus. Ann Intern Med 1996;124:97-103
62. Tattersall R. Traditional pharmacologic management of non-insulin dependent diabetes. Clin Invest Med 1995;18:288-295
63. Yki-Jarvinen H, Ryysy L, Nikkla K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: randomized controlled trial. Ann Intern Med 1999;130:389-396